GlassScriptPhysician profile
Bret A Cook
NPI 1184608994
$4,818.78
in general payments reported to CMS, 2019-2025
52 companies · $426 in 2025
The $426 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,159 · 2020: $369 · 2021: $197 · 2022: $1,346 · 2023: $1,322 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,491 · Education: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,490.74 |
| Education | $256.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $357.10 | 2019-2023 | Xospata |
| Astrazeneca Pharmaceuticals LP | $334.20 | 2019-2025 | Imfinzi, Enhertu, Tagrisso |
| Amgen INC. | $261.25 | 2019-2023 | Kyprolis, Nplate, Vectibix |
| Janssen Biotech, INC. | $247.10 | 2019-2025 | Rybrevant, Talvey, Darzalex |
| Pharmacyclics LLC, An Abbvie Company | $244.93 | 2019-2023 | Imbruvica |
| Merck Sharp & Dohme LLC | $215.83 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Regeneron Healthcare Solutions, INC. | $193.50 | 2020-2023 | Libtayo |
| Gilead Sciences, INC. | $178.89 | 2021-2023 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $178.50 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $167.93 | 2019-2025 | Opdivo |
| Eisai INC. | $167.41 | 2019-2023 | |
| Mirati Therapeutics, INC. | $166.79 | 2023 | Krazati |
| Abbvie INC. | $161.09 | 2019-2022 | |
| Lilly USA, LLC | $135.56 | 2019-2021 | |
| Incyte Corporation | $134.31 | 2019-2023 | Jakafi |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bret Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.